Halozyme Therapeutics, Inc. Financials

Market Capitalization $7.08 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	18.42
Forward PE	11.49
Price to Sales TTM	$7.47
Price to Book MRQ	$15.63
Enterprise to Revenue	8.39
Enterprise to EBITDA	14.37

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	41.43%
Operating Margin	56.26%
Return on Assets TTM	14.87%
Return on Equity TTM	111.83%

Income Statement

Revenue TTM	$947,355,008
Revenue per Share TTM	$7.43
Quarterly Revenue Growth	34.30%
Gross Profit TTM	$697,752,000
EBITDA	$558,599,000
Net Income to Common TTM	$392,467,008
Diluted EPS TTM	$3.02
Quarterly Earnings Growth YoY	67.40%

Balance Sheet

Total Cash MRQ	$666,305,984
Total Cash per Share MRQ	$5.24
Total Debt MRQ	$
Total Debt to Equity MRQ	339.05
Current Ratio MRQ	10.36
Book Value per Share MRQ	$3.56

Cash Flow

Operating Cash Flow TTM	$402,951,008
Levered Free Cash Flow TTM	$339,287,264

HALO Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	127,227,000
Float Shares	125,888,572
Avg 10 Volume	1,595,850
Avg 30 Volume	None
Shares Short	9,504,876
Short Ratio	7.28
Short % of Shares	10.11%
% Held by Insiders	1.06%
% Held by Institutions	101.56%

Stock Price Summary

Beta	1.29
Fifty Two Week Low	$33.15
Fifty Two Week High	$65.53
Fifty Two Week Change	38.30%
Day 50 MA	$50.23
Day 200 MA	$51.27

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date